康艾注射液联合CTF方案在乳腺癌新辅助化疗中的疗效与不良反应研究

摘要

目的 分析康艾注射液联合CTF方案化疗在乳腺癌新辅助化疗中的效果与不良反应.方法 选择2015年1月～2017年1月我院收治的经病理确诊为乳腺癌的女性患者60例,采用随机对照法分为对照组与观察组,对照组患者采用CTF方案新辅助化疗,观察组患者采用康艾注射液联合CTF方案新辅助化疗,比较两组患者的临床治疗总有效率、胃肠道反应、肝功能异常、肾功能异常、脱发、血小板减少等不良反应情况、治疗前后的生存质量评分.结果 ①观察组患者治疗总有效率高于对照组(P＜0.05);②观察组患者脱发、血小板减少不良反应发生情况优于对照组(P＜0.05);③观察组患者肝功能异常、肾功能异常、胃肠道反应与对照组比较,差异无统计学意义(P＞0.05);④观察组患者治疗后后生存质量各项评分均优于对照组(P＜0.05);⑤观察组患者治疗前生存质量各项评分与对照组比较,差异无统计学意义(P＞0.05).结论 在乳腺癌患者新辅助化疗中联合康艾注射液,有利于提高治疗效果,降低患者的脱发、血小板减少等不良反应,值得临床广泛推广和应用.%Objective To analyze the efficacy and adverse reactions of Kangai injection combined with CTF chemotherapy in neoadjuvant chemotherapy of breast cancer. Methods A total of 60 women diagnosed with breast cancer who were admitted to our hospital between January 2015 and January 2017 were selected and divided into a control group and an observation group by randomized methods. The control group received a new assistant with CTF. In the chemotherapy group, the patients in the observation group were treated with Kangai injection combined with CTF neoadjuvant chemotherapy, and the clinical treatment total effective rate, gastrointestinal reaction, abnormal liver function, abnormal renal function, alopecia, thrombocytopenia and other adverse reactions occurrence in the two groups and the quality of life before and after treatment served as a basis for comparison. Results ①The total effective rate of treatment in the observation group was higher than that in the control group(P＜0. 05);②The occurrence of adverse reactions to hair loss and thrombocytopenia in the observation group was superior to the control group(P＜0. 05);③The abnormal liver function was observed in the observation group. There was no significant difference in renal function abnormalities and gastroin testinal reactions between the control group and the observation group(P＞0. 05). ④The quality of life after treatment in the observation group was superior to that in the control group(P＜0. 05);⑤There was no significant difference in the quality of life of patients before treatment between the observation group and the control group(P＞0. 05). Conclusion This study proves that the combination of Kangai injection in neoadjuvant chemotherapy of breast cancer patients is beneficial to improve the treatment effect of patients and improve the occurrence of adverse reactions such as alopecia and thrombocytopenia in patients. It is worthy of promotion as the first choice for clinical treatment.